Experimental combo targets Hard-to-Treat sarcomas
NCT ID NCT05180695
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs—HDM201 and pazopanib—in people with advanced or metastatic soft tissue sarcoma that has a normal p53 gene. The trial has two parts: first, finding the safest dose of HDM201 when given with a fixed dose of pazopanib, and second, checking if the combination helps keep tumors from growing for at least 24 weeks. About 47 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HDM201 and pazopanib (Votrient)
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced soft tissue sarcoma, potentially slowing disease progression.
What could go wrong
This is an early-phase trial with only 47 participants, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69373, France
-
Institut Bergonié
Bordeaux, 33800, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut Paoli-Calmettes
Marseille, 13273, France